Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1,001 - 10,000 - Monthly Reach
Unique listeners across all episodes (30 days)
5,001 - 25,000 - Active Followers
Loyal subscribers who consistently listen
501 - 5,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 1 epsHost
Recent guests
Recent episodes
Episode 39: SV Health Investors' Kate Bingham
May 4, 2026
1h 12m 46s
Episode 38: Deerfield Management's Jason Fuller
Apr 20, 2026
Unknown duration
Episode 37: SR One's Simeon George
Mar 23, 2026
Unknown duration
Episode 36: Sofinnova Invetments' Jim Healy
Mar 9, 2026
Unknown duration
Episode 35: INITIATE Ventures' Jessica Owens
Feb 23, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/4/26 |  Episode 39: SV Health Investors' Kate Bingham✨ | investment approacheshealthcare+4 | Kate Bingham | SV HealthVertex+2 | — | Kate BinghamSV Health+5 | — | 1h 12m 46s | |
| 4/20/26 |  Episode 38: Deerfield Management's Jason Fuller | He discusses his education and joining the Langer Lab at MIT, early experiences in venture, including at Third Rock and NEA, and gaining operational experience at Jounce before joining Deerfield. Plus, areas that interest him today and how he thinks about AI. | — | ||||||
| 3/23/26 |  Episode 37: SR One's Simeon George | Simeon George discusses his early days at SR One while it was part of GSK, and the transition to making the firm independent in 2020. Plus, the importance of peer-to-peer collaboration, and his how he thinks about investing in different indications and modalities. | — | ||||||
| 3/9/26 |  Episode 36: Sofinnova Invetments' Jim Healy | He discusses learnings from his decades in venture at Sofinnova Investments including 'products vs platform', therapeutics areas of interest, modalities, and how he utilizes board seats and thinks about management teams. | — | ||||||
| 2/23/26 |  Episode 35: INITIATE Ventures' Jessica Owens | Jessica Owens discusses the many experiences she has had in her career, including working on the venture side at Kleiner Perkins and Versant Ventures and on the operating side at Genomic Health and Grail. She highlights the value of VCs being able to understand how operators like CEOs think, and describes the type of investing INITIATE focuses on. | — | ||||||
| 2/9/26 |  Episode 34: General Atlantic's Brett Zbar | Brett Zbar describes his early career, including working at Aisling Capital and Foresight Capital, and now managing the healthcare strategy at General Atlantic. He describes how he sees the difference between private equity and venture capital, and discusses which themes in biotech and healthcare appeal to him today. | — | ||||||
| 1/26/26 |  Episode 33: Pappas Capital's Art Pappas | Art Pappas describes his early career, which involved numerous overseas posts for large companies, and how it let him to eventually found Pappas Capital. He discusses the various ways the firm invests, and how having corporates partners as LPs and co-investors has been a recipe for success. | — | ||||||
| 1/11/26 |  Episode 32: ARCH Venture Partners' Bob Nelsen | While describing his early life in Washington and formative years at the University of Chicago that led to the founding of ARCH, he shares his thoughts on leadership, risk taking, changes he thinks are need to keep the United States competitive in life sciences, and his belief in AI's promise to transform our industry. | — | ||||||
| 12/29/25 |  Episode 31: Polaris Partners' Amy Schulman | She describes her career beginnings as a lawyer, which led to general counsel and business unit head roles at Pfizer, and then joining the VC world at Polaris Partners (at Bob Langer's urging). She discusses the firm's investment philosophy, the nuances behind how companies choose lead assets, and the cycles biotech has been through over the last ten years. Plus, other roles she currently serves, including being the chair of Alnylam. | — | ||||||
| 12/1/25 |  Episode 29: Averin Managing Partner David Berry | He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of healthcare and technology. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 11/10/25 |  Episode 28: Hatteras Venture Partners' Clay Thorp | Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in the North Carolina area, and his philosophy of backing founders. | — | ||||||
| 10/20/25 |  Episode 27: Avalon Bioventures' Jay Lichter | Jay Lichter describes his roots growing up in Chicago, Yale, and an early career role at DuPont Merck before getting a call from Kevin Kinsella to try the world of venture at Avalon. Since that pivotal move, he describes numerous companies he either operated or funded, leading to his work today at Avalon Bioventures. | — | ||||||
| 10/6/25 |  Episode 26: venBio's Corey Goodman | Corey Goodman shares learnings for his career in biotech, including working in academia, biotech, pharma, and as a venture capital investor. He describes the unique learnings from all of them and why he is thankful that he has experienced these different components of life sciences. | — | ||||||
| 9/22/25 |  Episode 25: Atlas Venture's Bruce Booth | Bruce Booth discusses his education and early career, the structure of Atlas and the types of investments it makes, investing in assets vs platforms, and more. | — | ||||||
| 8/11/25 |  Episode 24: Samsara Biocapital's Srini Akkaraju | The Founder & Managing Partner of Samsara Biocapital, Dr. Akkaraju describes his early move from Standford to industry and various investment firms he worked for before founding Samsara in 2016. He discusses how the firm invests in all stages of life sciences companies and why he believes patience is a key virtue. | — | ||||||
| 7/28/25 |  Episode 23: a16z's Vineeta Agarwala | Still a practicing physician today, Vineeta Agarwala describes her educational background and early career, including experiences at the Broad Institute, Flatiron Health, and GV (Google Ventures). She talks about a16z's investment philosophy of "providing more than just a check," and a recent $500M fund partnered with Lilly. | — | ||||||
| 6/30/25 |  Episode 22: Adjuvant Capital's Glenn Rockman | Glenn Rockman describes the introduction to impact investing he gained from working for J.P. Morgan and along with the Gates Foundation on the Global Health Investment Fund, and how the idea of investing for public good ultimately sparked Adjuvant Capital in 2019. Armed with a $300M+ fund that was raised from numerous foundations and for-profit funds in 2021, Adjuvant has been investing in public health technologies, post proof of concept, to help accelerate their development and ultimately make them more accessible to those around the world who need them. | — | ||||||
| 6/16/25 |  Episode 21: Scion Life Sciences' Aaron Kantoff | Aaron Kantoff describes the road on the public markets side that eventually led him to venture, and recalls successful investments he helped lead at firms like Apple Tree Partners and Medicxi, such as Stoke Therapeutics, Akero Therapeutics, Centessa Pharmaceuticals, and RayzeBio. He discusses founding Scion with his partner, Samuel Hall, and describes raising their first fund and how the firm has a longer outlook than is traditionally thought of in venture. | — | ||||||
| 6/2/25 |  Episode 20: Breakout Ventures' Lindy Fishburne | Lindy Fishburne describes her educational background and career, and transitioning from the philanthropic Breakout Labs within the Thiel Foundation to Breakout Ventures, a traditional venture firm that has a diverse set of limited partners. Plus, how she is navigating these challenging times in healthcare and biotech. | — | ||||||
| 5/19/25 |  Episode 19: Longwood Fund's Christoph Westphal | Dr. Westphal describes his upbringing and early career at McKinsey and Polaris, founding or co-founding companies like Momenta, Alnylam, Sirtris, Acceleron, and VeraStem, and creating the Longwood Fund. He shares his thoughts on venture investing, the current environment in biotech, focusing on creating new medicines, and his love of the Boston ecosystem. | — | ||||||
| 5/5/25 |  Episode 18: Playground Global's Jory Bell | Jory Bell shares the details of his expansive educational background and early career, which included being a product designer at Apple during the return of Steve Jobs. He describes Playground's engineering and tech angle to investing in life sciences, and weighs in on sizable seed and pre-seed investments the industry has seen lately that get startups to a proof of concept. | — | ||||||
| 4/21/25 |  Episode 17: Norwest Venture Partners' Tiba Aynechi | Tiba Aynechi describes her career path, which has been spent entirely in the Bay Area since she earned her PhD from UCSF in the early 2000's. She describes the value of BD experience she earned while working on licensing deals early in her career, her more than a decade at Novo Ventures, and what appealed to her to join Norwest. Plus, her thoughts on a board of directors' relationship with management teams. | — | ||||||
| 4/7/25 |  Episode 16: RA Capital's Josh Resnick | Josh Resnick describes his career path, which includes working on the venture side of both private funds and pharma (Merck). He explains the different investment strategies of RA Capital, and talks about how the firm's Raven company building incubator fits in. Plus, his thoughts on venture investing in the current environment. | — | ||||||
| 3/24/25 |  Episode 15: Mission BioCapital's Steve Tregay | Steve Tregay describes his career path, including how early roles at Array BioPharma and Novartis led him to found Forma Therapeutics. He describes the founding and growth of LabCentral, for which he is still the chairman today, and how getting a look at entrepreneurs at such an early stage naturally led to the investment work that he and his partners do at Mission BioCapital. | — | ||||||
| 3/10/25 |  Episode 14: Aditum Bio's Joe Jimenez | Joe Jimenez describes the career path in consumer products that led him to pharma, his time running Novartis, and the idea to co-found Aditum Bio with his partner Mark Fishman. He explains Aditum's investment philosophy, and why they like focusing on translational medicine opportunities that are just heading into the clinic. Plus, his thoughts on making R&D more efficient. | — | ||||||
Showing 25 of 38
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
11 placements across 9 markets.
Chart Positions
11 placements across 9 markets.